Bristol-Myers Squibb has signed up for another eight probody drug candidates from CytomX Therapeutics. Probodies are "masked" monoclonal antibodies that become activated when they interact with the tumor microenvironment.
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.